Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma

[1]  L. Pantanowitz,et al.  Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status , 2020, The American journal of surgical pathology.

[2]  H. Durán Sacristán,et al.  [Colorectal adenocarcinoma]. , 2020, Anales de la Real Academia Nacional de Medicina.

[3]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[4]  S. Mori,et al.  Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer , 2019, The British journal of surgery.

[5]  S. Carter,et al.  Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer , 2019, Clinical Cancer Research.

[6]  Caitlyn A. Miller,et al.  SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer , 2019, Modern Pathology.

[7]  S. Chiang,et al.  Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy , 2019, Journal of Cancer Research and Clinical Oncology.

[8]  Liron Pantanowitz,et al.  Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. , 2018, Oral oncology.

[9]  Michael Barnes,et al.  Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair–Deficient Colon Cancers: Implications for Prognosis , 2018, Clinical Cancer Research.

[10]  Ahmed Kamel,et al.  Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[12]  J. Church,et al.  Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer. , 2018, Annals of surgery.

[13]  R. Jorissen,et al.  Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes , 2018, Gut.

[14]  P. Laurent-Puig,et al.  Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. , 2017, European journal of cancer.

[15]  Phil Quirke,et al.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 , 2017, Modern Pathology.

[16]  Tracey F Lee-Pullen,et al.  Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response , 2017, Oncotarget.

[17]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[18]  K. Kawauchi,et al.  p53 regulates cytoskeleton remodeling to suppress tumor progression , 2015, Cellular and Molecular Life Sciences.

[19]  M. Kalady,et al.  American Joint Committee on Cancer and College of American Pathologists Regression Grade: A New Prognostic Factor in Rectal Cancer , 2015, Diseases of the colon and rectum.

[20]  M. Gönen,et al.  Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment. , 2014, Journal of the National Cancer Institute.

[21]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[22]  T. Beißbarth,et al.  Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Galon,et al.  Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014 .

[24]  H. Heneghan,et al.  Systematic review and meta‐analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer , 2012, The British journal of surgery.

[25]  M. Kurrer,et al.  Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer , 2012, Modern Pathology.

[26]  Sunil Krishnan,et al.  Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Terracciano,et al.  Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. , 2011, Human pathology.

[28]  H. Nagawa,et al.  Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer , 2011, Radiation oncology.

[29]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[30]  J. Melkko,et al.  Inflammation and prognosis in colorectal cancer. , 2005, European journal of cancer.

[31]  P. Conte,et al.  Incidence and Clinical Impact of Sterilized Disease and Minimal Residual Disease After Preoperative Radiochemotherapy for Rectal Cancer , 2005, Diseases of the colon and rectum.

[32]  L. Sobin,et al.  Colon and Rectum , 1998 .

[33]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[34]  J. Church,et al.  Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer. , 2019, Annals of Surgery.

[35]  A. Rogers,et al.  Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy , 2014, Modern Pathology.

[36]  C. Compton,et al.  Colon and Rectum , 2012 .